EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.

CONCLUSION: We conclude that co-delivery of Dox and Bcl-2-siRNA by tumor-targeted EGF-PEAL NPs could significantly inhibit lung cancer growth. PMID: 26739487 [PubMed - as supplied by publisher]
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research